Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 7, 2012, Pages 1187-1196

  Manzoni, Mariangela ^a   Mariucci, Sara ^a   Delfanti, Sara ^a   Rovati, Bianca ^a   Ronzoni, Monica ^b   Loupakis, Fotios ^c   Brugnatelli, Silvia ^a   Tinelli, Carmine ^a   Villa, Eugenio ^b   Falcone, Alfredo ^c   Danova, Marco ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Angiogenesis; Apoptosis; Biomarkers; Circulating endothelial cells; Colorectal cancer

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COUNT; CIRCULATING ENDOTHELIAL CELL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG RESPONSE; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; COLORECTAL NEOPLASMS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED;

EID: 84864344919     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1190-6     Document Type: Article

References (31)

1. Anonimus (2002) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med 48:206-208
2. Beerepoot LV, Mehra N et al (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15:139-145 (Pubitemid 38139616)
3. Bertolini F, Shaked Y et al (2006) The multifaceted circulating endothelial cell and cancer: towards marker and target identification. Nat Rev Cancer 6:835-845 (Pubitemid 44629895)
4. Bertolini F, Mancuso P et al (2007) Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 12:806-812 (Pubitemid 47539970)
5. Bertolini F, Mancuso P et al (2009) The multiple personality disorder phenotypes of circulating endothelial cells in cancer. Biochim Biophys Acta 1796:27-32
6. Bidard FC, Mathiot C et al (2010) Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with Bevacizumab and chemotherapy. Ann Oncol 21:1765-1771
7. Buyse M, Sargent DJ et al (2010) Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 7:309-317
8. Dellapasqua S, Bertolini F et al (2008) Metronomic cyclophosphamide and capecitabine combined with Bevacizumab in advanced breast cancer. J Clin Oncol 26:4899-4905
9. Duda DG, Ancukiewicz M et al (2010) Biomarkers of antiangiogenetic therapy: how do we move from candidate biomarkers to valid biomarkers? J Clin Oncol 28:183-185
10. Folkman J (1971) Tumor angiogenesis therapeutic implications. N Engl J Med 285:1182-1186
11. Goon PK, Boos CJ et al (2006) Detection and quantification of mature circulating endothelial cells using a flow cytometry and immunomagnetic beads: a methodological comparison. Tromb Haemost 96:45-52 (Pubitemid 44160870)
12. Goon PK, Lip GY et al (2009) Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/disfunction/apoptosis, clinicopathological factors and the Nottingham Prognostic Index. Neoplasia 11:771-779
13. Hurwitz H, Fehrenbacher L et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 23:2335-2342 (Pubitemid 38702844)
14. Jain RK, Duda DG et al (2009) Biomarkers of response and resistance to antiangiogenetic therapy. Nat Rev Clin Oncol 6:327-338
15. Khan SS, Solomon MA et al (2005) Detection of circulating endothelial cells and endothelial progenitors by flow cytometry. Cytom B Clin Cytom 64:1-8 (Pubitemid 40960406)
16. Mancuso P, Bertolini F (2010) Circulating endothelial cells as biomarkers in clinical oncology. Microvasc Res 79:224-228
17. Mancuso P, Burlini A et al (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658-3661
18. Mancuso P, Colleoni M et al (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108:452-459 (Pubitemid 44061341)
19. Mariucci S, Rovati B et al (2009) A six-colour flow cytometric method for simultaneous detection of cell phenotype and apoptosis of circulating endothelial cells. Scand J Clin Lab Invest 69:433-438
20. Mariucci S, Rovati B et al (2010) Flow cytometric detection of circulating endothelial cells and endothelial progenitor cells in healthy subjects. Int J Lab Hematol 32:40-44
21. Martin-Padura I, Bertolini F (2009) Circulating endothelial cells as biomarkers for angiogenesis in tumor progression. Front Biosci (Schol Ed) 1:304-318
22. McShane LM, Hunsberger S et al (2009) Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 15:1898-1905
23. Norden-Zfoni A, Desai J et al (2007) Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13:2643-2650 (Pubitemid 46788031)
24. Ranieri G, Patruno R et al (2006) Vascular endothelial growth factor (VEGF) as a target of Bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13:1845-1857
25. Ronzoni M, Manzoni M et al (2010) Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to Bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol 21:2382-2389
26. Rowand JL, Martin G et al (2007) Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 71A:105-113 (Pubitemid 46238939)
27. Strijbos MH, Gratama JW et al (2008) Circulating endothelial cells in oncology: pitfalls and promise. Br J Cancer 98:1731-1735 (Pubitemid 351748848)
28. Torrisi R, Bagnardi V et al (2008) Preoperative Bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 99:1564-1571
29. Welch S, Spithoff K et al (2010) Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 21:1152-1162
30. Wierzbowska A, Robak T et al (2008) Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients. Ann Hematol 87:97-106
31. Zhu AX, Sahani DV et al (2009) Efficacy, safety and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 18:3027-3035